<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Conditions associated with malignant hyperthermia or rhabdomyolysis related to anesthesia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Conditions associated with malignant hyperthermia or rhabdomyolysis related to anesthesia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Conditions associated with malignant hyperthermia or rhabdomyolysis related to anesthesia</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Condition</td> <td class="subtitle1" rowspan="2">Reported problems with anesthesia</td> <td class="subtitle1" rowspan="2">Genes potentially related to MH or anesthesia induced rhabdomyolysis</td> <td class="subtitle1" colspan="2">Recommendations for anesthesia</td> </tr> <tr> <td class="subtitle2">Volatile anesthetics</td> <td class="subtitle2">Succinylcholine</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Conditions associated with MH</td> </tr> <tr> <td class="indent1">MHS, no associated syndrome</td> <td>MH reactions</td> <td> <p><em>RYR1</em></p> <p><em>CACNA1S</em></p> <em>STAC3</em></td> <td>Contraindicated</td> <td>Contraindicated</td> </tr> <tr> <td class="indent1">Exertional rhabdomyolysis</td> <td>MH in some patients with <em>RYR1</em> pathogenic variants</td> <td><em>RYR1</em></td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants or rhabdomyolysis in unexpected situations*</td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants or rhabdomyolysis in unexpected situations*</td> </tr> <tr> <td class="indent1" colspan="5"><strong>Myopathies</strong></td> </tr> <tr> <td class="indent2">Central core myopathy</td> <td>High incidence of MH in patients with RYR1 receptor abnormality</td> <td><em>RYR1</em></td> <td>Contraindicated</td> <td>Contraindicated</td> </tr> <tr> <td class="indent2">Multiminicore myopathy</td> <td>High incidence of MH in patients with biallelic <em>RYR1</em> pathogenic variants</td> <td><em>RYR1</em></td> <td>Contraindicated</td> <td>Contraindicated</td> </tr> <tr> <td class="indent2">King-Denborough syndrome</td> <td>High incidence of MH in patients with RYR1 receptor abnormality</td> <td><em>RYR1</em></td> <td>Contraindicated</td> <td>Contraindicated</td> </tr> <tr> <td class="indent2">STAC3 (Native American) myopathy</td> <td>High incidence of MH in patients homozygous for <em>STAC3</em> pathogenic variant</td> <td><em>STAC3</em></td> <td>Contraindicated</td> <td>Contraindicated</td> </tr> <tr> <td class="indent2">Congenital myopathy with cores and rods</td> <td>MH in patient with multiple <em>RYR1</em> pathogenic variants</td> <td><em>RYR1</em></td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> <td>Contraindicated</td> </tr> <tr> <td class="indent2">Nemaline myopathy</td> <td>Uncomplicated use of succinylcholine and potent inhalational anesthesia has been reported, however there is insufficient evidence to support safety of succinylcholine</td> <td><em>RYR1</em></td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> <td>Contraindicated</td> </tr> <tr> <td class="indent2">Centronuclear myopathy (CNM)</td> <td>MH episodes likely only in patients with <em>RYR1</em> pathogenic variants (and possibly <em>CACNA1S</em> pathogenic variants, though these patients also typically have cores) and not in other subtypes</td> <td> <p><em>RYR1</em></p> <em>CACNA1S</em></td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> </tr> <tr> <td class="indent2">Congenital fiber type disproportion (CFTD)</td> <td>No reports of MH; 10 to 20% of patients with CFTD may have <em>RYR1</em> pathogenic variants</td> <td> <p><em>RYR1</em></p> <em>CACNA1S</em></td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> </tr> <tr> <td class="indent2">Periodic paralysis</td> <td> <p>MH in patients with <em>RYR1</em> pathogenic variant</p> <p>MHS has not been associated with <em>CACNA1S</em>-linked hypokalemic periodic paralysis</p> Atypical normokalemic periodic paralysis has been reported in a small number of patients with <em>RYR1</em> pathogenic variants</td> <td> <p><em>RYR1</em></p> <em>CACNA1S</em></td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> </tr> <tr> <td class="indent2">HyperCKemia</td> <td>MH in patients with <em>RYR1</em> pathogenic variants</td> <td><em>RYR1</em></td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants*</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Conditions associated with rhabdomyolysis</td> </tr> <tr> <td class="indent1">Exertional rhabdomyolysis</td> <td>MH in some patients with <em>RYR1</em> pathogenic variants</td> <td><em>RYR1</em></td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants or rhabdomyolysis in unexpected situations*</td> <td>Contraindicated in patients with <em>RYR1</em> pathogenic variants or rhabdomyolysis in unexpected situations*</td> </tr> <tr> <td class="indent1">Dystrophinopathies</td> <td> Patients with <em>DMD</em> pathogenic variants: <ul class="none"> <li>Severe hyperkalemia with succinylcholine; possible rhabdomyolysis or hyperkalemic cardiac arrest following volatile anesthetics</li> </ul> </td> <td><em>DMD</em></td> <td>Only if essential, in limited amounts, eg, for inhalational induction to establish venous access</td> <td>Contraindicated</td> </tr> <tr> <td class="indent1">Myoadenylate deaminase deficiency</td> <td>Rhabdomyolysis in patients homozygous for <em>AMPD1</em> pathogenic variant</td> <td><em>AMPD1</em></td> <td>Try to avoid in individuals homozygous for <em>AMPD1</em> pathogenic variant</td> <td>Try to avoid</td> </tr> <tr> <td class="indent1">Myophosphorylase deficiency (McArdle disease, glycogen storage disease V)</td> <td>In patients with <em>PYGM</em> pathogenic variant succinylcholine may exacerbate underlying symptoms</td> <td><em>PYGM</em></td> <td>Not contraindicated</td> <td> <p>Try to avoid</p> Avoid in patients with <em>PYGM</em> pathogenic variant*</td> </tr> <tr> <td class="indent1">Carnitine palmitoyl transferase type 2 deficiency</td> <td>Perioperative rhabdomyolysis in patients with <em>CPT2</em> pathogenic variants</td> <td><em>CPT2</em></td> <td>Not contraindicated; no evidence of superior safety with propofol</td> <td> <p>Try to avoid</p> Avoid in patients with <em>CPT2</em> pathogenic variant*</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Other conditions</td> </tr> <tr> <td class="indent1">Osteogenesis imperfecta</td> <td>Some reports of fever with anesthesia</td> <td> </td> <td>OK to use</td> <td>OK to use</td> </tr> <tr> <td class="indent1">Arthrogryposis multiplex congenita</td> <td> <p>Some reports of fever with anesthesia</p> Most cases have neurologic, not myopathic etiology</td> <td> <p><em>RYR1</em>, rare</p> Most cases have neurologic, not myopathic etiology</td> <td>OK to use in absence of <em>RYR1</em> pathogenic variants</td> <td>Avoid if suspected or confirmed myopathic etiology</td> </tr> <tr> <td class="indent1">Myotonia</td> <td> <p>Prolonged muscle rigidity after succinylcholine</p> Possible rigidity after anticholinesterase (NMBA reversal)</td> <td> </td> <td>OK to use</td> <td>Avoid succinylcholine or anticholinesterase reversal agents</td> </tr> <tr> <td class="indent1">Neuroleptic malignant syndrome</td> <td>Idiosyncratic reaction to antidopaminergics (eg, haloperidol, droperidol), usually more than 24 hours after administration</td> <td> </td> <td>OK to use</td> <td> <p>Contraindicated in patients with rhabdomyolysis</p> OK to use in patients without rhabdomyolysis</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>MH: malignant hyperthermia; MHS: malignant hyperthermia susceptible; <em>RYR1</em>: ryanodine receptor 1; <em>CACNA1S</em>: calcium voltage-gated channel subunit alpha1 S; <em>STAC3</em>: SH3 and cysteine-rich domains 3; <em>DMD</em>: dystrophin; <em>AMPD1</em>: Adenosine monophosphate deaminase-1; <em>PYGM</em>: phosphorylase, glycogen, muscle; <em>CPT2</em>: carnitine palmitoyltransferase 2.</p>
* This recommendation is applicable to patients with the specified pathogenic variant and to patients with unknown genetic test results.</div><div id="graphicVersion">Graphic 65645 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
